Lista de obras - Lisa Pieri - Dominio Público Uruguay

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

artículo científico publicado en 2014

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

artículo científico publicado en 2014

Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations.

artículo científico publicado en 2014

BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques

artículo científico publicado en 2012

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value

artículo científico publicado en 2014

Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study

artículo científico publicado en 2014

Chronic myeloproliferative neoplasms: a collaborative approach

artículo científico publicado en 2010

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

artículo científico publicado en 2014

Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients

artículo científico publicado en 2016

Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene

artículo científico publicado en 2014

Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2.

artículo científico publicado en 2013

Concomitant occurrence of BCR-ABL and JAK2V617F mutation

scientific article published on 01 September 2011

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

artículo científico publicado en 2016

Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis

artículo científico publicado en 2010

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

artículo científico publicado en 2011

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms

artículo científico publicado en 2015

Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression

artículo científico publicado en 2011

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia

artículo científico publicado en 2010

Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN.

artículo científico publicado en 2012

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

artículo científico publicado en 2010

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

artículo científico publicado en 2009

Imaging studies in extramedullary hematopoiesis of the spleen

artículo científico publicado en 2013

Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome.

artículo científico publicado en 2009

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

artículo científico publicado en 2013

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study

artículo científico publicado en 2014

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.

artículo científico publicado en 2014

Improving prognostic tools in systemic mastocytosis: Insights from mutations

artículo científico publicado en 2016

In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology

artículo científico publicado en 2014

Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

artículo científico

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia

artículo científico publicado en 2008

Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis

artículo científico publicado en 2013

Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.

artículo científico publicado en 2012

JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.

artículo científico publicado en 2011

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

artículo científico publicado en 2015

JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

artículo científico publicado en 2008

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

artículo científico publicado en 2014

MR Imaging in non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis.

artículo científico publicado en 2016

Masked polycythemia vera (mPV): results of an international study

artículo científico publicado en 2013

Mesenchymal stem cells from JAK2V617F mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele

artículo científico publicado en 2007

Mutations and prognosis in primary myelofibrosis

artículo científico publicado en 2013

Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis

scientific article published on 24 September 2015

Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis

artículo científico publicado en 2015

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

artículo científico publicado en 2016

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

scientific article published on 11 February 2008

Risk of second cancers in chronic myeloproliferative neoplasms

artículo científico publicado en 2012

Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia.

artículo científico publicado en 2015

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

artículo científico publicado en 2011

Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms

artículo científico publicado en 2013

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis

artículo científico publicado en 2015

The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera

artículo científico publicado en 2009

The burden of symptoms in myelofibrosis: from patient-reported outcomes to health economics

artículo científico publicado en 2013

The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia.

artículo científico publicado en 2010

Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.

artículo científico publicado en 2015

Treatment options for essential thrombocythemia and polycythemia vera

scientific article published on February 2009

Lista de obras de Lisa Pieri

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations.

BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value

Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study

Chronic myeloproliferative neoplasms: a collaborative approach

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients

Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene

Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2.

Concomitant occurrence of BCR-ABL and JAK2V617F mutation

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms

Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia

Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN.

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

Imaging studies in extramedullary hematopoiesis of the spleen

Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome.

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.

Improving prognostic tools in systemic mastocytosis: Insights from mutations

In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology

Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia

Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis

Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.

JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

MR Imaging in non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis.

Masked polycythemia vera (mPV): results of an international study

Mesenchymal stem cells from JAK2V617F mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele

Mutations and prognosis in primary myelofibrosis

Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis

Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

Risk of second cancers in chronic myeloproliferative neoplasms

Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia.

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis

The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera

The burden of symptoms in myelofibrosis: from patient-reported outcomes to health economics

The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia.

Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.

Treatment options for essential thrombocythemia and polycythemia vera